Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352252 | 0.87 | GAA (0.50) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL4900433 | 0.84 | GAA (0.48) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL12568166 | 0.82 | GAA (0.47) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL2302254 | 0.82 | GAA (0.50) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL316348 | 0.82 | SMN1; SMN2 (0.48) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL1933229 | 0.82 | GAA (0.47) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL1463814 | 0.82 | GAA (0.47) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL4889822 | 0.81 | GAA (0.46) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL23783503 | 0.79 | GAA (0.44) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL20467895 | 0.79 | GAA (0.44) | GAAKDM4EKMT2AMAOBMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127371-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127371-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TNNI3, TNNT2, REN | GAA 2828/4885KDM4E 3219/4885KMT2A 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.